Developer docs
API playgroundTry for free, no card

Search company profiles

StemRIM

Full company profile

uuid0006856

Namestring
StemRIM
Legal namestring
株式会社ステムリム
Websiteurl
stemrim.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

StemRIM Inc. (株式会社ステムリム) is a clinical-stage Japanese biotechnology company founded in 2006 and headquartered in Ibaraki City, Osaka, that develops Regeneration-Inducing Medicine™ — a class of chemically synthesized peptides derived from the active domain of the human HMGB1 protein. The company's lead compound, Redasemtide (development code TRIM2), mobilizes the patient's own mesenchymal stem cells from bone marrow into the bloodstream, where they accumulate at sites of tissue damage and exert immunomodulatory, trophic, and anti-fibrotic effects to promote functional tissue regeneration. StemRIM is currently advancing Redasemtide in Phase 2 clinical trials for five indications: dystrophic epidermolysis bullosa (DEB), acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease, and is additionally developing next-generation peptides (TRIM3, TRIM4, TRIM5) and an autologous stem-cell gene therapy (SR-GT1) for DEB. The company is pre-revenue with zero operating revenue in FY2025, supported by ¥6.99B of cash and a runway into 2028.

The business model is a capital-light, out-licensed R&D platform. StemRIM generated the foundational IP through a long-standing collaborative research relationship with Osaka University (since 2007) and operates the jointly-controlled StemRIM Institute of Regeneration-Inducing Medicine on the Suita Campus. In 2014, StemRIM out-licensed global development and commercialization rights to Redasemtide to Shionogi & Co., Ltd., under which Shionogi funds and runs all corporate-sponsored clinical trials while StemRIM conducts investigator-initiated trials with university partners (Osaka, Niigata, Hirosaki) and receives upfront, milestone, and royalty payments. Additional revenue streams include joint-research income from collaborations (Osaka University, Shiseido anti-aging research) and non-dilutive grants from Japanese government agencies (AMED, JST, NEDO). The company has secured Orphan Drug Designation for Redasemtide and built a multi-jurisdictional patent estate covering the platform and its indications.

StemRIM has 69 employees as of July 31, 2025, and is listed on the Tokyo Stock Exchange Growth Market under securities code 4599, with 62,136,200 issued shares and 22,373 shareholders. R&D expenses for FY2025 totaled ¥1,394,651 thousand against zero operating revenue, producing an operating loss of approximately ¥13.1B and a net loss of ¥12.8B. The company executed a ¥106,400 thousand capital reduction in July 2025 to repair the balance sheet ahead of further clinical-stage spending. Leadership is anchored by President & CEO Masatsune Okajima (appointed CEO October 2023, ex-Medicinova, Daiwa Securities) and Founder/CSO Professor Katsuto Tamai, who continues as Guest Professor at Osaka University.

Short descriptiontext

StemRIM is a clinical-stage Japanese biotech developing Regeneration-Inducing Medicine™ — synthetic HMGB1-derived peptides (lead: Redasemtide) that mobilize endogenous stem cells to repair damaged tissue, out-licensed to Shionogi for indications including epidermolysis bullosa, stroke, and cardiomyopathy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIbaraki, Japan
HQ citystring
Ibaraki
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, peptide drug discovery, stem cell therapy, biotech pharmaceuticals, clinical drug development
Industry5 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing Revenue (Shionogi & Co., Ltd.)
TypeLicensing Royalties
Description

Out-licensing agreement with Shionogi for Redasemtide (HMGB1 peptides). Expected revenue streams include upfront payments upon contract signing, milestone payments at each development stage achievement, and royalty income as a fixed percentage of product sales after commercialization.

stemrim.com
2Joint Research Income
TypeProfessional Services
Description

Income obtained as remuneration for conducting joint research using company intellectual property with partners such as Osaka University, Shiseido, and others.

stemrim.com
3Milestone Income
TypeOthers
Description

Lump-sum income obtained each time set targets for each development stage (development milestone) are reached, or after product launch when sales target values (sales milestone) are achieved.

stemrim.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

StemRIM develops Regeneration-Inducing Medicines, a novel class of peptide drugs based on HMGB1 fragment peptides that activate and mobilize the patient's own endogenous mesenchymal stem cells from bone marrow to damaged tissues for functional regeneration. The lead compound Redasemtide (TRIM2) is in Phase 2 clinical trials for five indications including dystrophic epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease. The company out-licenses Redasemtide to Shionogi & Co., Ltd. for development and commercialization while conducting investigator-initiated trials in partnership with Japanese universities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 clinical trial results for dystrophic epidermolysis bullosa: 7 of 9 patients showed symptom improvement, 4 showed significant improvement with long-lasting therapeutic effects
+2 more records
Product overview1 text field

StemRIM is a biotechnology company developing Regeneration-Inducing Medicine™, a novel platform technology based on HMGB1 peptides that activate the body's own stem cells to induce functional tissue regeneration. The core product portfolio includes Redasemtide (TRIM2) as the first approved/clinical-stage Regeneration-Inducing Medicine™, along with next-generation candidates TRIM3 and TRIM4 (novel peptides), TRIM5 (stem cell guidance molecule), and SR-GT1 (stem cell gene therapy). All products share the common mechanism of mobilizing or guiding endogenous mesenchymal stem cells to damaged tissues for regeneration, offering a platform approach across multiple disease areas.

Product and service5 records
1Redasemtide (TRIM2)
CategoryRegeneration-Inducing Medicine (Peptide Drug)
Description

The first Regeneration-Inducing Medicine, a chemically synthesized HMGB1 fragment peptide administered intravenously that mobilizes the patient's own mesenchymal stem cells from bone marrow into the bloodstream, where they accumulate at damaged tissue sites to promote functional tissue regeneration through immunomodulation, trophic effects, and fibrosis suppression. In Phase 2 clinical trials for five indications: dystrophic epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease. Out-licensed to Shionogi & Co., Ltd. for development and commercialization.

2TRIM3 Peptide
CategoryRegeneration-Inducing Medicine (Peptide Drug)
Description

Next-generation Regeneration-Inducing Medicine peptide that mobilizes mesenchymal stem cells residing in the bone marrow. Developed using proprietary peptide design and screening methods for activating mesenchymal stem cells, representing an advancement beyond the first-generation TRIM2 platform.

3TRIM4 Peptide
CategoryRegeneration-Inducing Medicine (Peptide Drug)
Description

Next-generation Regeneration-Inducing Medicine peptide that mobilizes mesenchymal stem cells residing in the bone marrow. Developed using proprietary peptide design and screening methods for activating mesenchymal stem cells, designed to address limitations of first-generation approaches.

4TRIM5 (Stem Cell Guidance Molecule)
CategoryRegeneration-Inducing Medicine (Chemokine Molecule)
Description

A chemokine-based molecule that guides innate mesenchymal stem cells to damaged tissue. Injected around lesions to attract circulating stem cells to treatment areas, addressing cases where insufficient SDF-1alpha secretion limits natural stem cell migration to damaged tissues.

5SR-GT1 (Stem Cell Gene Therapy)
CategoryStem Cell Gene Therapy
Description

Gene therapy for dystrophic epidermolysis bullosa using the patient's own mesenchymal stem cells harvested from blisters, transduced with lentiviral vector carrying functional collagen type VII gene, expanded, and administered back to the patient. Aims at curative treatment by delivering functional collagen VII gene to the patient's own stem cells ex vivo.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2014-01-01
Description

Licensing agreement for HMGB1 peptides (Redasemtide) where Shionogi manages development and commercialization. Shionogi conducts corporate-sponsored clinical trials for acute ischemic stroke and holds rights for multiple indications including epidermolysis bullosa, cardiomyopathy, knee osteoarthritis, and chronic liver disease. Company receives upfront, milestone, and royalty payments.

2Osaka University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing collaborative research relationship since 2007. Co-founded StemRIM Institute of Regeneration-Inducing Medicine (1,540 sqm facility) on Suita Campus. Professor Katsuto Tamai serves as Scientific Founder and Guest Professor. Joint research in stem cell biology, regenerative medicine, and drug discovery.

stemrim.com
3Niigata University
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research partnership with Professor Shuji Terai's team conducting investigator-initiated Phase 2 clinical trial for Redasemtide in chronic liver disease. Research on HMGB1 peptide effects on liver inflammation and fibrosis published in scientific journals.

stemrim.com
4Hirosaki University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Investigator-initiated Phase 2 clinical trial site for Redasemtide in knee osteoarthritis.

stemrim.com
5Shiseido Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Trilateral research agreement for anti-aging research project related to skin, involving Osaka University. Extended in January 2025.

stemrim.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Visit to StemRIM Institute of Regeneration-Inducing Medicine as part of Osaka University collaboration promotion meeting.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1AnGes, Inc.
TypeRegional player
Description

Japan-based clinical-stage biotechnology company developing gene therapy and nucleic acid medicines. Comparable as a Japanese small-cap biotech with similar development-stage profile, though focused on different therapeutic modalities (DNA vaccines, gene therapy).

TypeDirect peer
Description

Clinical-stage biotechnology company developing mesenchymal stem cell (MSC) therapies for inflammatory diseases, cardiovascular conditions, and orthopedic indications. Closely comparable given StemRIM's MSC-mobilization mechanism and overlapping therapeutic areas (cardiomyopathy, osteoarthritis).

TypeDirect peer
Description

Japanese regenerative medicine company developing stem cell therapies (Multistem) for stroke, ARDS, and other conditions. Directly comparable as a Japan-based clinical-stage regenerative medicine company pursuing indications that overlap with StemRIM's pipeline (notably acute stroke).

4Cynata Therapeutics Limited
TypeEmerging player
Description

Clinical-stage company developing Cymerus, a MSC product derived from induced pluripotent stem cells (iPSC), for conditions including osteoarthritis and graft-versus-host disease. Comparable as a developer of MSC-based therapies targeting overlapping indications.

5RegeneRx Biopharmaceuticals, Inc.
TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing thymosin beta 4-based peptide therapeutics for tissue regeneration and repair. Comparable as a peptide-based regenerative medicine company with similar mechanism philosophy (using small molecules/peptides rather than cells to induce tissue repair).

TypeBroad incumbent
Description

Established Japanese biopharmaceutical company with a regenerative medicine franchise (e.g., TEMCELL HS Inj. for GvHD, a registered allogeneic MSC product). Comparable as a Japan-based biopharma with approved cell-based regenerative therapies targeting similar patient populations.

TypeRegional player
Description

Korean biopharmaceutical company marketing CARTISTEM (allogeneic umbilical cord blood-derived MSC product) for knee osteoarthritis. Directly comparable for the knee osteoarthritis indication, though Medipost is a regional competitor with an approved cell-based product.

TypeDirect peer
Description

Commercial-stage company selling cell therapy products (MACI for cartilage repair) and burn care products. Directly comparable given StemRIM's knee osteoarthritis and epidermolysis bullosa indications, though Vericel uses a cell-based rather than peptide-based approach.

9Pluristem Therapeutics Inc.
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing placenta-derived cell therapies (PLX cells) for multiple indications including muscle injury and critical limb ischemia. Comparable for its MSC-based approach to regenerative medicine and similar multi-indication pipeline strategy.

10Athersys, Inc.
TypeEmerging player
Description

Clinical-stage biotechnology company developing MultiStem cell therapy for stroke, ARDS, and other conditions. Comparable as a stem cell therapy developer with overlapping acute ischemic stroke indication, though Athersys uses ex vivo expanded allogeneic cells rather than endogenous mobilization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemRIM

Regenerative Medicine Pharmaceuticalsstemrim.com

StemRIM is a clinical-stage Japanese biotech developing Regeneration-Inducing Medicine™ — synthetic HMGB1-derived peptides (lead: Redasemtide) that mobilize endogenous stem cells to repair damaged tissue, out-licensed to Shionogi for indications including epidermolysis bullosa, stroke, and cardiomyopathy.

What StemRIM does

StemRIM Inc. (株式会社ステムリム) is a clinical-stage Japanese biotechnology company founded in 2006 and headquartered in Ibaraki City, Osaka, that develops Regeneration-Inducing Medicine™ — a class of chemically synthesized peptides derived from the active domain of the human HMGB1 protein. The company's lead compound, Redasemtide (development code TRIM2), mobilizes the patient's own mesenchymal stem cells from bone marrow into the bloodstream, where they accumulate at sites of tissue damage and exert immunomodulatory, trophic, and anti-fibrotic effects to promote functional tissue regeneration. StemRIM is currently advancing Redasemtide in Phase 2 clinical trials for five indications: dystrophic epidermolysis bullosa (DEB), acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease, and is additionally developing next-generation peptides (TRIM3, TRIM4, TRIM5) and an autologous stem-cell gene therapy (SR-GT1) for DEB. The company is pre-revenue with zero operating revenue in FY2025, supported by ¥6.99B of cash and a runway into 2028.

The business model is a capital-light, out-licensed R&D platform. StemRIM generated the foundational IP through a long-standing collaborative research relationship with Osaka University (since 2007) and operates the jointly-controlled StemRIM Institute of Regeneration-Inducing Medicine on the Suita Campus. In 2014, StemRIM out-licensed global development and commercialization rights to Redasemtide to Shionogi & Co., Ltd., under which Shionogi funds and runs all corporate-sponsored clinical trials while StemRIM conducts investigator-initiated trials with university partners (Osaka, Niigata, Hirosaki) and receives upfront, milestone, and royalty payments. Additional revenue streams include joint-research income from collaborations (Osaka University, Shiseido anti-aging research) and non-dilutive grants from Japanese government agencies (AMED, JST, NEDO). The company has secured Orphan Drug Designation for Redasemtide and built a multi-jurisdictional patent estate covering the platform and its indications.

StemRIM has 69 employees as of July 31, 2025, and is listed on the Tokyo Stock Exchange Growth Market under securities code 4599, with 62,136,200 issued shares and 22,373 shareholders. R&D expenses for FY2025 totaled ¥1,394,651 thousand against zero operating revenue, producing an operating loss of approximately ¥13.1B and a net loss of ¥12.8B. The company executed a ¥106,400 thousand capital reduction in July 2025 to repair the balance sheet ahead of further clinical-stage spending. Leadership is anchored by President & CEO Masatsune Okajima (appointed CEO October 2023, ex-Medicinova, Daiwa Securities) and Founder/CSO Professor Katsuto Tamai, who continues as Guest Professor at Osaka University.

StemRIM firmographics

Firmographics
Name
StemRIM
Legal name
株式会社ステムリム
Website
https://stemrim.com
Company type
Public
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
StemRIM is a clinical-stage Japanese biotech developing Regeneration-Inducing Medicine™ — synthetic HMGB1-derived peptides (lead: Redasemtide) that mobilize endogenous stem cells to repair damaged tissue, out-licensed to Shionogi for indications including epidermolysis bullosa, stroke, and cardiomyopathy.
Ownership category
akta.pro rank

StemRIM industry classification

Industry
Product category
Regenerative Medicine Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAJ
Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Peptide drug discovery
  • Stem cell therapy
  • Biotech pharmaceuticals
  • Clinical drug development

Where StemRIM is headquartered

Location

Headquarters

HQ city
Ibaraki
HQ country
Japan
HQ region
Asia

Offices3 records

Markets served

StemRIM business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Licensing Revenue (Shionogi & Co., Ltd.): Out-licensing agreement with Shionogi for Redasemtide (HMGB1 peptides). Expected revenue streams include upfront payments upon contract signing, milestone payments at each development stage achievement, and royalty income as a fixed percentage of product sales after commercialization.
  2. Joint Research Income: Income obtained as remuneration for conducting joint research using company intellectual property with partners such as Osaka University, Shiseido, and others.
  3. Milestone Income: Lump-sum income obtained each time set targets for each development stage (development milestone) are reached, or after product launch when sales target values (sales milestone) are achieved.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

StemRIM product offering

Product offering

Core offering

StemRIM develops Regeneration-Inducing Medicines, a novel class of peptide drugs based on HMGB1 fragment peptides that activate and mobilize the patient's own endogenous mesenchymal stem cells from bone marrow to damaged tissues for functional regeneration. The lead compound Redasemtide (TRIM2) is in Phase 2 clinical trials for five indications including dystrophic epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease. The company out-licenses Redasemtide to Shionogi & Co., Ltd. for development and commercialization while conducting investigator-initiated trials in partnership with Japanese universities.

Product overview

StemRIM is a biotechnology company developing Regeneration-Inducing Medicine™, a novel platform technology based on HMGB1 peptides that activate the body's own stem cells to induce functional tissue regeneration. The core product portfolio includes Redasemtide (TRIM2) as the first approved/clinical-stage Regeneration-Inducing Medicine™, along with next-generation candidates TRIM3 and TRIM4 (novel peptides), TRIM5 (stem cell guidance molecule), and SR-GT1 (stem cell gene therapy). All products share the common mechanism of mobilizing or guiding endogenous mesenchymal stem cells to damaged tissues for regeneration, offering a platform approach across multiple disease areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • Redasemtide (TRIM2) The first Regeneration-Inducing Medicine, a chemically synthesized HMGB1 fragment peptide administered intravenously that mobilizes the patient's own mesenchymal stem cells from bone marrow into the bloodstream, where they accumulate at damaged tissue sites to promote functional tissue regeneration through immunomodulation, trophic effects, and fibrosis suppression. In Phase 2 clinical trials for five indications: dystrophic epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease. Out-licensed to Shionogi & Co., Ltd. for development and commercialization.
  • TRIM3 Peptide Next-generation Regeneration-Inducing Medicine peptide that mobilizes mesenchymal stem cells residing in the bone marrow. Developed using proprietary peptide design and screening methods for activating mesenchymal stem cells, representing an advancement beyond the first-generation TRIM2 platform.
  • TRIM4 Peptide Next-generation Regeneration-Inducing Medicine peptide that mobilizes mesenchymal stem cells residing in the bone marrow. Developed using proprietary peptide design and screening methods for activating mesenchymal stem cells, designed to address limitations of first-generation approaches.
  • TRIM5 (Stem Cell Guidance Molecule) A chemokine-based molecule that guides innate mesenchymal stem cells to damaged tissue. Injected around lesions to attract circulating stem cells to treatment areas, addressing cases where insufficient SDF-1alpha secretion limits natural stem cell migration to damaged tissues.
  • SR-GT1 (Stem Cell Gene Therapy) Gene therapy for dystrophic epidermolysis bullosa using the patient's own mesenchymal stem cells harvested from blisters, transduced with lentiviral vector carrying functional collagen type VII gene, expanded, and administered back to the patient. Aims at curative treatment by delivering functional collagen VII gene to the patient's own stem cells ex vivo.

Quantifiable outcome

  • Phase 2 clinical trial results for dystrophic epidermolysis bullosa: 7 of 9 patients showed symptom improvement, 4 showed significant improvement with long-lasting therapeutic effects
  • +2 more outcomes

Companies that use StemRIM

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles2 records

StemRIM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

StemRIM partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Shionogi & Co., Ltd.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2014Licensing agreement for HMGB1 peptides (Redasemtide) where Shionogi manages development and commercialization. Shionogi conducts corporate-sponsored clinical trials for acute ischemic stroke and holds rights for multiple indications including epidermolysis bullosa, cardiomyopathy, knee osteoarthritis, and chronic liver disease. Company receives upfront, milestone, and royalty payments.
  • Osaka UniversitycoreStrategic or Co-development PartnerLong-standing collaborative research relationship since 2007. Co-founded StemRIM Institute of Regeneration-Inducing Medicine (1,540 sqm facility) on Suita Campus. Professor Katsuto Tamai serves as Scientific Founder and Guest Professor. Joint research in stem cell biology, regenerative medicine, and drug discovery.
  • Niigata UniversitycoreStrategic or Co-development PartnerJoint research partnership with Professor Shuji Terai's team conducting investigator-initiated Phase 2 clinical trial for Redasemtide in chronic liver disease. Research on HMGB1 peptide effects on liver inflammation and fibrosis published in scientific journals.
  • Hirosaki UniversityminorStrategic or Co-development PartnerInvestigator-initiated Phase 2 clinical trial site for Redasemtide in knee osteoarthritis.
  • Shiseido Co., Ltd.minorStrategic or Co-development PartnerTrilateral research agreement for anti-aging research project related to skin, involving Osaka University. Extended in January 2025.
  • Japan Post Life Insurance (かんぽ 생명)minorStrategic or Co-development PartnerVisit to StemRIM Institute of Regeneration-Inducing Medicine as part of Osaka University collaboration promotion meeting.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

StemRIM competitors and assessment

Company assessment

Regional players

  • AnGes, Inc. Japan-based clinical-stage biotechnology company developing gene therapy and nucleic acid medicines. Comparable as a Japanese small-cap biotech with similar development-stage profile, though focused on different therapeutic modalities (DNA vaccines, gene therapy).
  • Medipost Co., Ltd. Korean biopharmaceutical company marketing CARTISTEM (allogeneic umbilical cord blood-derived MSC product) for knee osteoarthritis. Directly comparable for the knee osteoarthritis indication, though Medipost is a regional competitor with an approved cell-based product.

Direct peers

  • Mesoblast Limited: Clinical-stage biotechnology company developing mesenchymal stem cell (MSC) therapies for inflammatory diseases, cardiovascular conditions, and orthopedic indications. Closely comparable given StemRIM's MSC-mobilization mechanism and overlapping therapeutic areas (cardiomyopathy, osteoarthritis).
  • Healios K.K. Japanese regenerative medicine company developing stem cell therapies (Multistem) for stroke, ARDS, and other conditions. Directly comparable as a Japan-based clinical-stage regenerative medicine company pursuing indications that overlap with StemRIM's pipeline (notably acute stroke).
  • Vericel Corporation: Commercial-stage company selling cell therapy products (MACI for cartilage repair) and burn care products. Directly comparable given StemRIM's knee osteoarthritis and epidermolysis bullosa indications, though Vericel uses a cell-based rather than peptide-based approach.
  • Pluristem Therapeutics Inc. Clinical-stage regenerative medicine company developing placenta-derived cell therapies (PLX cells) for multiple indications including muscle injury and critical limb ischemia. Comparable for its MSC-based approach to regenerative medicine and similar multi-indication pipeline strategy.

Emerging players

  • Cynata Therapeutics Limited: Clinical-stage company developing Cymerus, a MSC product derived from induced pluripotent stem cells (iPSC), for conditions including osteoarthritis and graft-versus-host disease. Comparable as a developer of MSC-based therapies targeting overlapping indications.
  • RegeneRx Biopharmaceuticals, Inc. Clinical-stage biopharmaceutical company developing thymosin beta 4-based peptide therapeutics for tissue regeneration and repair. Comparable as a peptide-based regenerative medicine company with similar mechanism philosophy (using small molecules/peptides rather than cells to induce tissue repair).
  • Athersys, Inc. Clinical-stage biotechnology company developing MultiStem cell therapy for stroke, ARDS, and other conditions. Comparable as a stem cell therapy developer with overlapping acute ischemic stroke indication, though Athersys uses ex vivo expanded allogeneic cells rather than endogenous mobilization.

Broad incumbents

  • JCR Pharmaceuticals Co., Ltd. Established Japanese biopharmaceutical company with a regenerative medicine franchise (e.g., TEMCELL HS Inj. for GvHD, a registered allogeneic MSC product). Comparable as a Japan-based biopharma with approved cell-based regenerative therapies targeting similar patient populations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

StemRIM social profiles

Digital presence

StemRIM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemRIM leadership team

Management profile

Number of profiles

Profiles8 records

StemRIM subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

StemRIM funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemRIM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemRIM

What does StemRIM do?

StemRIM develops Regeneration-Inducing Medicines, a novel class of peptide drugs based on HMGB1 fragment peptides that activate and mobilize the patient's own endogenous mesenchymal stem cells from bone marrow to damaged tissues for functional regeneration. The lead compound Redasemtide (TRIM2) is in Phase 2 clinical trials for five indications including dystrophic epidermolysis bullosa, acute ischemic stroke, ischemic cardiomyopathy, knee osteoarthritis, and chronic liver disease. The company out-licenses Redasemtide to Shionogi & Co., Ltd. for development and commercialization while conducting investigator-initiated trials in partnership with Japanese universities.

Is StemRIM a public or private company?

StemRIM is a public company. It is classified as public and is currently operating.

When was StemRIM founded?

StemRIM was founded in 2006. It employs 1 to 10 people.

Where is StemRIM based?

StemRIM is headquartered in Ibaraki, Japan, in the Asia region.

How does StemRIM make money?

Three revenue lines are on record. Licensing Revenue (Shionogi & Co., Ltd.) is the primary driver. The others are joint Research Income and milestone Income.

Who are StemRIM's main competitors?

Regional players on record are AnGes, Inc. and Medipost Co., Ltd.. Direct peers are Mesoblast Limited, Healios K.K., Vericel Corporation and Pluristem Therapeutics Inc.. Emerging players are Cynata Therapeutics Limited, RegeneRx Biopharmaceuticals, Inc. and Athersys, Inc.. JCR Pharmaceuticals Co., Ltd. is listed as a broad incumbent.

Does StemRIM have an API?

No public API is recorded for StemRIM.

What industry is StemRIM in?

StemRIM's product category is Regenerative Medicine Pharmaceuticals. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals